

Special Issue

Mucocutaneous Manifestations of HIV after 40 Years from the First Case

Message from the Guest Editors

The year 1991 represents a crucial year for the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) epidemic. In June of that year, the Center for Disease Control (CDC) reported two clusters of rare diseases, *Pneumocystis carinii* pneumonia and Kaposi's Sarcoma, respectively, which mostly affected gay American men, previously healthy. Since then, the scientific community has been tirelessly devoted to investigating etiopathogenesis, diagnosis, prevention and treatment, achieving important successes. Most patients show at least one mucocutaneous HIV/AIDS-related manifestation in their clinical history; it often occurs at the early onset of the infection and correlates with the immunologic stage and the use of highly active antiretroviral therapy (HAART). We kindly invite clinical and basic researchers to submit original research, review or expert opinion articles about pathogenesis, diagnosis and treatment of HIV/AIDS, with a particular focus on skin and oral disorders.

Guest Editors

Dr. Elena Varoni

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy

Prof. Dr. Giovanni Lodi

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/72756

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).